Holen Sie sich die Stockscreener-App
24.21
0.88%
0.21
Handel nachbörslich:
24.40
0.19
+0.78%
Schlusskurs vom Vortag:
$24.00
Offen:
$24.04
24-Stunden-Volumen:
948.02K
Relative Volume:
0.66
Marktkapitalisierung:
$212.22M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-121.02M
KGV:
-2.1501
EPS:
-11.26
Netto-Cashflow:
$-114.09M
1W Leistung:
-6.88%
1M Leistung:
-28.82%
6M Leistung:
-15.82%
1J Leistung:
+77.23%
1-Tages-Spanne:
$23.76
$24.78
1-Wochen-Bereich:
$23.60
$27.33
52-Wochen-Spanne:
$7.31
$130.00
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Firmenname
Tonix Pharmaceuticals Holding Corp
Sektor
Branche
Telefon
212-980-9155
Adresse
26 MAIN STREET, SUITE 101, CHATHAM, NY
Vergleichen Sie TNXP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
24.21 | 210.38M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.74 | 97.91B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.90 | 58.88B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.40 | 58.93B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
711.62 | 43.52B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
326.06 | 36.11B | 3.81B | -644.79M | -669.77M | -6.24 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-04-18 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-04-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Bestätigt | Oppenheimer | Outperform |
| 2015-11-04 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-12 | Eingeleitet | Oppenheimer | Outperform |
| 2015-02-17 | Bestätigt | ROTH Capital | Buy |
| 2014-09-29 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten
13,670 Shares in Tonix Pharmaceuticals Holding Corp. $TNXP Purchased by Rhumbline Advisers - MarketBeat
Tonix advances TNX-102 SL for depression after positive FDA meeting boosts development path - Proactive financial news
What is Zacks Small Cap's Estimate for TNXP FY2025 Earnings? - MarketBeat
Tonix Pharma Licenses Rights to Lyme Disease Antibody - MSN
Daily Brief Health Care: Shandong Weigao Blood Purification Products, TYK Medicines, Butong Group, Alteogen Inc, SBC Medical Group Holdings , Achieve Life Sciences , Tonix Pharmaceuticals Holding and more - Smartkarma
Tonix gains global rights to TNX-4800, developing one-dose seasonal protection for Lyme disease - Proactive financial news
TNXP: Tonmya™ Approved by FDA… - Zacks Small Cap Research
Tonix Pharmaceuticals Holding Corp.(NasdaqCM: TNXP) added to S&P Global BMI Index - MarketScreener
Tonix plans IND filing for depression treatment after FDA meeting By Investing.com - Investing.com Nigeria
Analyst Downgrade: Is now the right time to enter Tonix Pharmaceuticals Holding CorpWeekly Risk Report & Low Drawdown Investment Strategies - خودرو بانک
Tonix plans IND filing for depression treatment after FDA meeting - Investing.com India
Tonix Pharma Completes FDA Meeting for TNX-102 SL - TipRanks
Fed Watch: Can LeddarTech Holdings Inc Equity Warrant navigate macro headwindsQuarterly Risk Review & Low Risk Entry Point Tips - خودرو بانک
Tonix Pharmaceuticals (TNXP) Advances Toward New Depression Trea - GuruFocus
Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder - The Manila Times
Tonix Pharmaceuticals Announces Plans for IND Filing of TNX-102 SL for Major Depressive Disorder Following Positive FDA Pre-IND Meeting - Quiver Quantitative
Tonix reports positive pre-IND FDA meeting for TNX-102 SL in major depressive disorder treatment - MarketScreener
Tonix Reports Positive Pre-IND FDA Meeting for TNX-102 SL in Major Depressive Disorder Treatment - TradingView
Tonix Pharmaceuticals Announces Positive Pre-IND Meeting - GlobeNewswire
FDA-Approved Fibromyalgia Drug TNX-102 SL Shows Promise for Major Depression Treatment - Stock Titan
Revolutionary 1-shot Lyme disease prevention approved - Rolling Out
Tonix Pharmaceuticals (TNXP) Gains on Lyme Disease Treatment Lic - GuruFocus
Tonix licenses monoclonal antibody for Lyme disease prevention By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals gets global rights to Lyme disease treatment - Seeking Alpha
Tonix Pharmaceuticals (TNXP) Secures Rights to Potential Lyme Di - GuruFocus
Tonix Pharmaceuticals Secures Rights to Lyme Disease Prevention Candidate - MarketScreener
Tonix Pharmaceuticals announces in-licensing of worldwide rights to TNX-4800 - TipRanks
Tonix licenses monoclonal antibody for Lyme disease prevention - Investing.com
Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800) - The Manila Times
Tonix Pharmaceuticals In-Licenses TNX-4800 for Lyme Disease Prevention Following Positive Phase 1 Study Results - Quiver Quantitative
Tonix Pharmaceuticals Announces In-licensing Phase - GlobeNewswire
70M Americans Could Benefit: Tonix's New Once-Yearly Antibody Shows Promise in Preventing Lyme Disease - Stock Titan
UMass Chan licenses monoclonal antibody for seasonal prevention of Lyme disease to Tonix Pharmaceuticals - UMass Chan Medical School
Is Tonix Pharmaceuticals Holding Corp stock risky to hold nowLayoff News & Safe Capital Investment Plans - خودرو بانک
Pattern recognition hints at Tonix Pharmaceuticals Holding Corp. upsideJuly 2025 EndofMonth & Intraday High Probability Alerts - newser.com
Investment Recap: Will Tonix Pharmaceuticals Holding Corp announce a stock splitPortfolio Value Summary & Verified Entry Point Detection - خودرو بانک
Aug Fed Impact: What are analysts price targets for Tonix Pharmaceuticals Holding CorpMarket Performance Recap & High Conviction Trade Alerts - خودرو بانک
What’s the RSI of Tonix Pharmaceuticals Holding Corp. stockMarket Risk Report & Momentum Based Trading Ideas - خودرو بانک
Sell Signal: Is Tonix Pharmaceuticals Holding Corp. exposed to currency risksWeekly Market Outlook & Accurate Trade Setup Notifications - khodrobank.com
Bull Bear: Does Tonix Pharmaceuticals Holding Corp offer margin of safetyRisk Management & Technical Confirmation Trade Alerts - خودرو بانک
Published on: 2025-09-15 21:26:59 - خودرو بانک
Aug EndMonth: Will Tonix Pharmaceuticals Holding Corp stock benefit from M ADividend Hike & Stepwise Entry/Exit Trade Alerts - خودرو بانک
Tonix showcases Phase 3 data for FDA-approved Tonmya at PAINWEEK 2025, eyes launch next quarter - Proactive financial news
Tonix Pharmaceuticals : September 2025 Investor Deck - MarketScreener
Published on: 2025-09-08 16:12:23 - beatles.ru
Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the - GuruFocus
Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025 - Yahoo Finance
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Why Tonix Pharmaceuticals Holding Corp. (TNXP) Soared Last Week - MSN
Combining machine learning predictions for Tonix Pharmaceuticals Holding Corp.Wall Street Watch & Safe Capital Growth Tips - Newser
Is Tonix Pharmaceuticals Holding Corp. stock entering bullish territoryJuly 2025 Review & AI Optimized Trade Strategies - Newser
Finanzdaten der Tonix Pharmaceuticals Holding Corp-Aktie (TNXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tonix Pharmaceuticals Holding Corp-Aktie (TNXP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Treco James | Director |
Aug 20 '25 |
Buy |
36.00 |
250 |
9,000 |
250 |
| LEDERMAN SETH | Chief Executive Officer |
May 15 '25 |
Buy |
21.55 |
4,000 |
86,200 |
4,005 |
3.41%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):